Advertisement
Advertisement
February 19, 2012
ReCor Medical Receives CE Mark Approval for Paradise Renal Denervation System
February 20, 2012—ReCor Medical, Inc. (Ronkonkoma, NY) announced that its Paradise percutaneous renal denervation system has received CE Mark approval for the treatment of patients with resistant hypertension.
According to the company, the Paradise system includes a 6-F-compatible catheter with a cylindrical transducer that emits ultrasound energy circumferentially, allowing for a rapid and highly efficient renal denervation procedure. The device uniformly denervates all the way around the arterial wall while simultaneously cooling the endothelium to help enable a safe, consistent, and fast renal denervation procedure.
Thomas A. Mabin, MD, presented data from the first-in-man REDUCE clinical study at the TREND 2012 transcatheter renal denervation scientific meeting in Frankfurt, Germany. The data showed that systolic blood pressure was reduced by an average of 31 mm Hg in seven patients at 60-day follow-up after treatment with Paradise, stated the company.
“The initial results with Paradise are impressive,” commented Prof. Marc Sapoval, MD. “This degree of blood pressure reduction has significant health benefits for patients.”
Advertisement
Advertisement
